With the availability of a method of purifying plasminogen from human Fraction IIL8 the therapeutic use of this enzyme in thrombotic conditions became a distinct possibility. Before attempting the clinical use of purified plasminogen, however, it appeared advisable to investigate the reporte that the enzyme responsible for the fibrinolytic activity can be separated from the agent producing prot...

Thrombolytic therapy is the modality of choice for the treatment of life threatening thrombosis in various vascular territories and nowadays, is used extensively in the setting of acute myocardial infarction. There is, however, the omnipresent danger of serious bleeding inherently associated with the use of all thrombolytics which if it occurs in the brain, can lead to potentially serious neuro...

stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage...

Inferior vena cava (IVC) filter thrombosis has not been described as a clinical entity. Thirty patients with IVC percutaneous filter thrombosis were assessed by cavography, computed tomographic (CT) scan and/or duplex ultrasonography. All patients had proximal venous thrombosis when the filter was placed, and the indication for filter placement was a contraindication to anticoagulant therapy in...

In infants, the most common cause of femoral artery is thrombosis and iatrogenic arterial injuries usually occur after femoral artery catheterization procedures. Management of this complication includes heparin infusion, thrombolytic agents, interventional radiologic procedures, surgical thrombectomy and by-pass surgery. Signs of arterial thrombosis developed after femoral artery catheterizatio...

Although the serine protease, tissue plasminogen activator (tPA), is approved by the US Food and Drug Administration for therapy to combat focal cerebral infarction, the basic concept of thrombolytic tPA therapy for stroke was challenged by recent studies that used genetically manipulated tPA-deficient (tPA-/-) mice, which suggested that tPA mediates ischemic neuronal damage. However, those stu...

Deep vein thrombosis is a frequent complication following total joint arthroplasty and other major orthopedic procedures. Pulmonary embolism occurs with or without a diagnosis of deep vein thrombosis, although infrequently (1.5%-10%). In patients with congenital cardiac defects, such as a patent foramen ovale, paradoxical cerebral embolism may also occur. This article describes a case of a 52-y...